{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T11:41:20Z","timestamp":1763811680516,"version":"3.40.5"},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Duchenne muscular dystrophy (DMD) is characterized by progressive, irreversible muscle damage that usually leads to premature death from cardiac or respiratory failure. Eteplirsen is a phosphorodiamidate morpholino oligomer and the first antisense oligonucleotide (ASO) approved for the treatment of patients with exon 51 skip\u2010amenable DMD. This analysis presents the first population pharmacokinetics (PK) modeling and simulation performed for the ASO drug class in DMD. Study objectives were to characterize the population PK of eteplirsen in patients with DMD across a broad age range and to identify the impact of covariates on eteplirsen exposure to guide clinical dosing. Plasma concentration data were pooled from six clinical studies of male patients with DMD across the age range of 6\u2009months to 4\u2009years (1 study) and 4\u201316\u2009years (5 studies). Doses ranged from 0.5 to 50\u2009mg\/kg\/week across different studies. A three\u2010compartment model with a linear elimination described the eteplirsen plasma concentration data well. Body weight effect on all PK parameters and eGFR, and age (\u2264\u20094\u2009years vs. &gt;\u20094\u2009years) effect on systemic clearance were key determinants of variability in the final model. Simulations showed similar exposures for eteplirsen (30\u2009mg\/kg intravenously once weekly) across different age groups (0.5 to &lt;\u20092, 2 to &lt;\u20094, 4 to &lt;\u20097, and 7 to \u2264\u200916\u2009years). These findings support the existing eteplirsen dosing paradigm of uniform weight\u2010based dosing at 30\u2009mg\/kg\/week across the broad age range of the target DMD population (6\u2009months to adolescence).<\/jats:p>","DOI":"10.1002\/psp4.70001","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T22:50:31Z","timestamp":1741733431000},"page":"891-903","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad <scp>DMD<\/scp> Population"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4629-6148","authenticated-orcid":false,"given":"Yogesh","family":"Patel","sequence":"first","affiliation":[{"name":"Sarepta Therapeutics, Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Orogun","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Yocum","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise R.","family":"Rodino\u2010Klapac","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilly","family":"East","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0960-8966(91)90039-U"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2012.301"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-2044"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0631-3"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01430-8"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00248-3"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210678"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21808"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052512"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/currents.RRN1297"},{"issue":"2","key":"e_1_2_10_13_1","first-page":"149","article-title":"The NorthStar Ambulatory Assessment in Duchenne Muscular Dystrophy: Considerations for the Design of Clinical Trials","volume":"87","author":"Ricotti V.","year":"2016","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32910-1"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25185"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82725-z"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-019-00242-6"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.287"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23982"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20918"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300095"},{"key":"e_1_2_10_22_1","unstructured":"\u201cExondys 51 (Eteplirsen) Injection for Intravenous Use [Package Insert] \u201d (2022) accessed December 9 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/206488s027s028s029lbl.pdf."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/1091581811403504"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/1091581811403505"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/1091581809359206"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-160157"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1264"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009233"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27347"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2023.03.008"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210643"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24555"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200548"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60756-3"},{"key":"e_1_2_10_35_1","unstructured":"National Library of Medicine \u201cClinicalTrials.gov. Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy: Results Overview (NCT02420379) \u201d accessed December 9 2024 https:\/\/clinicaltrials.gov\/study\/NCT02420379?term=NCT02420379&rank=1&tab=results."},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21420"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.07.010"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-021-01122-x"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0134-5"},{"key":"e_1_2_10_41_1","unstructured":"Centers for Disease Control and Prevention \u201cNational Health and Nutrition Examination Survey \u201d accessed December 9 2024 https:\/\/www.cdc.gov\/nchs\/nhanes\/."},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.08.004"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27107"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.2000.89.1.81"},{"volume-title":"Presented at the 13th International Meeting of the International Society for the Study of Xenobiotics, September 11\u201314, 2022, Seattle, Washington, USA","author":"Mukashyaka M. C.","key":"e_1_2_10_45_1"}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.70001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:31:25Z","timestamp":1747153885000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.70001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1002\/psp4.70001"],"URL":"https:\/\/doi.org\/10.1002\/psp4.70001","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"type":"print","value":"2163-8306"},{"type":"electronic","value":"2163-8306"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"2024-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}